Time-resolved immunofluorometric assay of trypsin-1 complexed with α1- antitrypsin in serum: Increased immunoreactivity in patients with biliary tract cancer

Clinical Chemistry

Volumn 45, Issue 10, 1999, Pages 1768-1773

  Hedström, Johan ^a,b   Haglund, Caj ^a   Kemppainen, Esko ^a   Leinimaa, Maarit ^a   Leinonen, Jari ^a   Stenman, Ulf Håkan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOCHEMICAL MARKER; CA 19-9 ANTIGEN; POLYCLONAL ANTIBODY; TRYPSIN; TRYPSINOGEN;

ARTICLE; BILIARY TRACT CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FLUOROMETRY; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

EID: 0032832844     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.10.1768     Document Type: Article

References (27)

1. 1. Figarella C, Amouric M, Carrere J, Miszczuk Jamska B, Guy Crotte O. Pancreatic proteins in normal state and pancreatic diseases in pancreatic juice and blood. Ric Clin Lab 1984;14:349-59.
2. 2. Mallory PA, Travis J. Human pancreatic enzymes: characterization of anionic human trypsin. Biochemistry 1973;12:2847-51.
3. 3. Figarella C, Clemente F, Guy O. On zymogens of human pancreatic juice. FEBS Lett 1969;3:351-3.
4. 4. Borgstrom A, Ohlsson K. Studies on the turnover of endogenous cathodal trypsinogen in man. Eur J Clin Investig 1978;8:379-82.
5. 5. Ohlsson K. Acute pancreatitis. Biochemical, pathophysiological and therapeutical aspects. Acta Gastroenterol Belg 1988;51:3-12.
6. 1-antitrypsin in serum. Clin Chem 1994;40:1761-5.
7. 7. Borgstrom A, Ohlsson K. Immunoreactive trypsin in serum and peritoneal fluid in acute pancreatitis. Hoppe Seylers Z Physiol Chem 1978;359:677-81.
8. 1-protease inhibitor complexes in serum and clinical course of acute pancreatitis. Scand J Gastroenterol 1984;19:1119-22.
9. 9. Hedström J, Sainio V, Kemppainen E, Haapiainen R, Kivilaakso E, Schröder T, et al. Serum complex of trypsin-2 and α-1 antitrypsin as a diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. Br Med J 1996;313:333-7.
10. 10. Koivunen E, Huhtala M-L, Stenman U-H. Human ovarian tumor-associated trypsin: its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989;264:14095-9.
11. 11. Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen Y, Bergmann U, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997:272:21067-74.
12. 12. Koivunen E, Saksela O, Itkonen O, Osman S, Huhtala M-L, Stenman U-H. Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer 1991;47:592-6.
13. 13. Koivunen E, Itkonen O, Halila H, Stenman U-H. Cyst fluid of ovarian cancer patients contain high concentrations of trypsinogen-2. Cancer Res 1990;50:2375-8.
14. 14. Koivunen E, Ristimäki A, Itkonen O, Osman S, Vuento M, Stenman U-H. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 1991:51:2107-12.
15. 15. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987;907:191-217.
16. 16. Ohta T, Terada T, Nagakawa T, Tajima H, Itoh H, Fonseca L, et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994;69:152-6.
17. 17. Terada T, Ohta T, Minato H, Nakanuma Y. Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocar-cinomas and hepatocellular carcinomas. Hum Pathol 1995;26:746-52.
18. 18. Terada T, Nakanuma Y. Immunohistochemical demonstration of pancreatic a-amylase and trypsin in intrahepatic bile ducts and peribiliary glands. Hepatology 1991;14:1129-35.
19. 19. Terada T, Kida T, Nakanuma Y. Extrahepatic peribiliary glands express α-amylase isozymes, trypsin and pancreatic lipase: an immunohistochemical analysis. Hepatology 1993:14:803-8.
20. 1-antitrypsin complex in malignant and benign digestive tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer 1996;66:326-31.
21. 21. Itkonen O, Koivunen E, Hurme M, Alfthan H, Schröder T, Stenman UH. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 1990:115:712-8.
22. 22. Hemmilä I, Dakubu S, Mukkala V-M, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 1984:137:335-43.
23. 23. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA19-9. Clin Chem 1983;29:549-52.
24. 24. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves. Radiology 1983:148:839-43.
25. 25. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O, Jalanko H. Evaluation of CA19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986:53:197-202.
26. 1-antitrypsin in human sera. Scand J Clin Lab Investig 1984;44:381-6.
27. 27. Borgstrom A, Lasson A, Ohlsson K. Patterns of immunoreactive trypsin in serum from patients with acute abdominal disorders. Scand J Clin Lab Investig 1989;49:757-62.